Table 4.
Reported somatic markers of Barrett’s esophagus progression to dysplasia/adenocarcinoma
| Marker | Individual study | Association (meta-analysis/individual study) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LOE | Variant | Gene | Association | EV | LOE | Ethnicity | Phenotype | Adjusted for confounders? | ||||||
| Variant | None | Phenotype and OR/HR (95 % CI) | I 2 | Chi | p | n | ||||||||
| II | CIN | NA | Bird-Lieberman et al. [36] | CIN | C | NP | HGD/EAC | Yes (plus length, dysplasia) | HGD/EAC OR(A) IM PB 5.98 (2.10–17.1) | 57 % | 16.2 | 8.00 × 10−4 | 5 | |
| Sikkema et al. [37] | CIN | C | Cauc | HGD/EAC | Yes (plus dysplasia) | HGD/EAC HR(A) IM 1.36 (1.26–1.47) | 0 % | 0.98 | <1.00 × 10−5 | 2 | ||||
| Chao et al. [57]* | CIN | C | NP | EAC | No | |||||||||
| Galipeau et al. [38]* | CIN | C | NP | EAC | Yes (length, not dysplasia) | PB-adjusted for publication bias Fang 2004, Rabinovitch 2001, | ||||||||
| Fang et al. [58] | CIN | C | NP | EAC | No | |||||||||
| Maley et al. [39]* | CIN | C | NP | EAC | Yes (length, not dysplasia) | Teodori 1999 | ||||||||
| Rabinovitch et al. [59]* | CIN | C | NP | EAC | Yes (length, not dysplasia) | |||||||||
| Reid et al. [9]** | CIN | D | NP | EAC | No | Overlapping populations*** | ||||||||
| Teodori et al. [60] | CIN | C | NP | HGD/EAC | No | |||||||||
| Reid et al. [8]** | CIN | C | NP | EAC | No | |||||||||
| James et al. [61] | CIN | D | NP | EAC | No | |||||||||
| III | CNV | NA | Paulson et al. [62] | >70 Mbp | C | NP | EAC/CIN | No | EAC/CIN HR 4.90 (1.60–14.8) | NA | NA | 4.70 × 10−3 (NS) | 1 | |
| III | LOH | TP53 | Galipeau et al. [38]* | LOH | C | NP | EAC | Yes (length, not dysplasia) | EAC HRA 5.4 (2.5–12.0) | NA | NA | <1 × 10−3 | 1 | |
| Maley et al. [39]* | LOH | C | ||||||||||||
| Reid et al. [63]* | LOH | C | ||||||||||||
| III | LOH | P16 | Galipeau et al. [38]* | Maley et al. [39]* | LOH | C | NP | EAC | Yes (length, not dysplasia) | EACA HR 2.4 (1.0–5.5) | NA | NA | 0.045 | 1 |
| LOH | C | NP | EAC | Yes (length, not dysplasia) | ||||||||||
| III | Mutant | TP53 | Galipeau et al. [38]* | Mutant | C | NP | EAC | No | EAC HRA 1.27 (1.07–1.50) | NA | NA | <0.01 (NS) | 1 | |
| Maley et al. [39]* | Mutant | C | NP | EAC | Yes (length, not dysplasia) | |||||||||
| Dolan et al. [64] | Mutant | C | NP | EAC | No | No meta possible as study population overlap and differing effect measures | ||||||||
LOE level of evidence, EV effect variant, OR odds ratio, HR hazard ratio, CI confidence interval, CIN chromosomal instability, NA not applicable, NP not presented, NS nonsignificant, HGD high-grade dysplasia, EAC esophageal adenocarcinoma, A adjusted
*,**,*** denote overlapping populations